Clinical Research Directory
Browse clinical research sites, groups, and studies.
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
Sponsor: Boehringer Ingelheim
Summary
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
Official title: A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD)
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
299
Start Date
2024-03-29
Completion Date
2025-04-30
Last Updated
2026-06-23
Healthy Volunteers
No
Conditions
Interventions
JARDIANCE®
JARDIANCE®
Locations (12)
Hallym University Sacred Heart Hospital
Anyang, South Korea
Chungbuk National University Hospital
Cheongiu, South Korea
Yonsei University Wonju Severance Christian Hospital
Gangwon, South Korea
Inje University Ilsan Paik Hospital
Goyang, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Korea University Anam Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, South Korea
Soonchunhyang University Hospital Seoul
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea, Yeouido St.Mary's Hospital
Seoul, South Korea
Ulsan University Hospital
Ulsan, South Korea